These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15749640)

  • 1. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.
    Dumontet C; Isaac S; Souquet PJ; Bejui-Thivolet F; Pacheco Y; Peloux N; Frankfurter A; Luduena R; Perol M
    Bull Cancer; 2005 Feb; 92(2):E25-30. PubMed ID: 15749640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
    Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of beta-tubulin isotypes in human primary ovarian carcinoma.
    Ohishi Y; Oda Y; Basaki Y; Kobayashi H; Wake N; Kuwano M; Tsuneyoshi M
    Gynecol Oncol; 2007 Jun; 105(3):586-92. PubMed ID: 17343904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Class III beta tubulin expression in nonsmall cell lung cancer].
    Sève P; Dumontet C
    Rev Mal Respir; 2010 Apr; 27(4):383-6. PubMed ID: 20403547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel.
    Sève P; Mackey J; Isaac S; Trédan O; Souquet PJ; Pérol M; Lai R; Voloch A; Dumontet C
    Mol Cancer Ther; 2005 Dec; 4(12):2001-7. PubMed ID: 16373715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
    Du J; Li B; Fang Y; Liu Y; Wang Y; Li J; Zhou W; Wang X
    BMC Cancer; 2015 Jul; 15():536. PubMed ID: 26198101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer.
    Hayashi Y; Kuriyama H; Umezu H; Tanaka J; Yoshimasu T; Furukawa T; Tanaka H; Kagamu H; Gejyo F; Yoshizawa H
    Intern Med; 2009; 48(4):203-8. PubMed ID: 19218769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
    Dumontet C; Jordan MA; Lee FF
    Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. βIII-Tubulin: biomarker of taxane resistance or drug target?
    Karki R; Mariani M; Andreoli M; He S; Scambia G; Shahabi S; Ferlini C
    Expert Opin Ther Targets; 2013 Apr; 17(4):461-72. PubMed ID: 23379899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.
    Yang YL; Luo XP; Xian L
    PLoS One; 2014; 9(4):e93997. PubMed ID: 24705847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.
    Vilmar AC; Santoni-Rugiu E; Sørensen JB
    Clin Cancer Res; 2011 Aug; 17(15):5205-14. PubMed ID: 21690572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
    Sève P; Dumontet C
    Lancet Oncol; 2008 Feb; 9(2):168-75. PubMed ID: 18237851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
    Galmarini CM; Treilleux I; Cardoso F; Bernard-Marty C; Durbecq V; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A; Dumontet C
    Clin Cancer Res; 2008 Jul; 14(14):4511-6. PubMed ID: 18628466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
    Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
    Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.